EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives

Omar Alomari iD, Habiba Eyvazova, Beyzanur Güney, Rana Al Juhmani iD, Hatice Odabasi iD, Lubna Al-Rawabdeh iD, Muhammed Edib Mokresh iD, Ufuk Erginoglu iD, Abdullah Keles, Mustafa K Baskaya

Cancers · 01.08.2025 · 17 (15) · 2550

DOI: 10.3390/cancers17152550 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 01.08.2025. Verfasst von Omar Alomari und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hamidiye International School of Medicine, University of Health Sciences, 34668 Istanbul, Türkiye. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, necessitating novel therapeutic approaches. Oncolytic treatments, particularly oncolytic viruses (OVs), have emerged as promising candidates by selectively infecting and lysing tumor cells while stimulating anti-tumor immunity. Various virus-based therapies are under investigation, including genetically engineered herpes simplex virus (HSV), adenovirus, poliovirus, reovirus, vaccinia virus, measles virus, and Newcastle disease virus, each exploiting unique tumor-selective mechanisms. While some, such as HSV-based therapies including G207 and DelytactTM, have demonstrated clinical progress, significant challenges persist, including immune evasion, heterogeneity in patient response, and delivery barriers due to the blood–brain barrier. Moreover, combination strategies integrating OVs with immune checkpoint inhibitors, chemotherapy, and radiation are promising but require further clinical validation. Non-viral oncolytic approaches, such as tumor-targeting bacteria and synthetic peptides, remain underexplored. This review highlights current advancements while addressing critical gaps in the literature, including the need for optimized delivery methods, better biomarker-based patient stratification, and a deeper understanding of GBM’s immunosuppressive microenvironment. Future research should focus on enhancing OV specificity, engineering viruses to deliver therapeutic genes, and integrating OVs with precision medicine strategies. By identifying these gaps, this review provides a framework for advancing oncolytic therapies in GBM treatment.

Schlagwörter

Stichwörter der Autor:innen

GBMOncoviralblood-brain barrierimmunotherapy

Autor:innen und Institutionen

  • Hamidiye International School of Medicine, University of Health Sciences, 34668 Istanbul, Türkiye.
  • Faculty of Medicine, Baskent University, 06790 Ankara, Türkiye.
  • Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, 34865 Istanbul, Turkey.
  • School of Medicine, Yarmouk University, Irbid 21163, Jordan.
  • Department of Neurosurgery, University of Wisconsin School of Medicine, Madison, WI 53706, USA.

ORCID-Profile: Omar Alomari, Rana Al Juhmani, Hatice Odabasi, Lubna Al-Rawabdeh, Muhammed Edib Mokresh, Ufuk Erginoglu

Zitieren

APA

Alomari, O., Eyvazova, H., Güney, B., Al Juhmani, R., Odabasi, H., Al-Rawabdeh, L., Mokresh, M. E., Erginoglu, U., Keles, A., & Baskaya, M. K. (2025). Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives. Cancers, 17(15), 2550. https://doi.org/10.3390/cancers17152550

Vancouver

Alomari O, Eyvazova H, Güney B, Al Juhmani R, Odabasi H, Al-Rawabdeh L, et al. Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives. Cancers. 2025;17(15):2550. doi:10.3390/cancers17152550

BibTeX
@article{Alomari2025,
  author = {Alomari, Omar and Eyvazova, Habiba and Güney, Beyzanur and Al Juhmani, Rana and Odabasi, Hatice and Al-Rawabdeh, Lubna and Mokresh, Muhammed Edib and Erginoglu, Ufuk and Keles, Abdullah and Baskaya, Mustafa K},
  title = {Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {15},
  pages = {2550},
  doi = {10.3390/cancers17152550}
}
Kostenlos starten →